To Prime, or Not to Prime: That Is the Question
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Mitochondrial priming is regulated by the B-cell lymphoma 2 (BCL-2) family of proteins and determines a cell's "readiness" for apoptosis. A highly primed cell will undergo apoptosis more easily than an unprimed cell in response to apoptotic stimuli via the intrinsic apoptotic pathway. Priming can be measured via BH3 profiling, which uses BH3 peptides derived from the BH3 domain of pro-apoptotic BH3-only BCL-2 family members to provoke a response from viable mitochondria. BH3 profiling can be performed on tumor cells and can identify mechanisms a cell uses to evade apoptosis and anti-apoptotic dependency to the anti-apoptotic BCL-2 family members. Priming correlates with chemosensitivity of patients in multiple cancers. Therapeutics that enhances priming of patient tumor cells ex vivo could be used to aid therapeutic decisions for patients in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · cited 1×
“In multiple myeloma, serum levels of the monoclonal protein (M protein) are measured as an indication of tumor burden (Durie et al. 2006).”
BackgroundABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · cited 2×
“A clinical derivative of ABT-737 is navitoclax (ABT263), an orally bioavailable BH3 mimetic (Tse et al. 2008).”
BackgroundLetai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677 · cited 7×
“Short synthetic BH3 peptides were used to investigate BCL-2 family member interactions and showed that BIM and BID BH3 peptides cause BAX and BAK oligomerization (Letai et al. 2002; Certo et al. 2006).”
BackgroundMethodInfluentialSelf-citationLindsten, T., Ross, A. J., King, A., Zong, W.-X., Rathmell, J. C., Shiels, H. A., Ulrich, E., Waymire, K. G., Mahar, P., Frauwirth, K., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00136-2 · Cited by 1,489 · cited 1×
“BAK and BAX are functionally redundant; however, loss of both prevents intrinsic apoptosis, showing that BAX and BAK are essential for MOMP (Lindsten et al. 2000).”
BackgroundStructure of Bcl-x L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis
Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., Chang, B. S., Minn, A. J., et al. (1997) · Science · doi:10.1126/science.275.5302.983 · Cited by 1,476 · cited 2×
“The BH3 domain was first described in BIK more than 20 years ago (Boyd et al. 1995) and is essential for interactions among BCL-2 members (Zha et al. 1996; Sattler et al. 1997).”
BackgroundKuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185 · cited 1×
“Studies on the BH3 domain of PUMA (antagonist to all anti-apoptotic BCL-2 family members) showed no activator function (Letai et al. 2002; Kuwana et al. 2005; Certo et al. 2006).”
BackgroundHierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies
Kim, H., Rafiuddin-Shah, M., Tu, H.-C., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J.-D., & Cheng, E. H.-Y. (2006) · Nature Cell Biology · doi:10.1038/ncb1499 · Cited by 874 · cited 1×
“However, studies using full protein show that PUMA has activator properties (Kim et al. 2006).”
BackgroundGandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6208 · Cited by 603 · cited 5×
“Combing navitoclax with targeted agents such as MEK (MAPK/ERK kinase), mTOR (mammalian target of rapamycin), or PI3K (phosphoinositide 3-kinase) inhibitors appears to increase the potency of navitoclax in preclinical models in NSCLC (non– small cell lung cancer), pancreatic cancer, and SCLC (Tan et al. 2013; Faber et…”
BackgroundInfluentialDrug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.042 · Cited by 378 · cited 1×
“Delta priming can be used to predict a therapy’s cytotoxic response in vitro, in vivo, and importantly in the clinic (Montero et al. 2015).”
Self-citation
Cited by
Marchi, S., Giorgi, C., Galluzzi, L., & Pinton, P. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.017 · Cited by 235
Serrat, N., Guerrero-Hernández, M., Matas-Céspedes, A., Yahiaoui, A., Valero, J. G., Nadeu, F., Clot, G., Di Re, M., Corbera-Bellalta, M., Magnano, L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001584 · Cited by 32
“In summary, immune microenvironment renders FL more dependent on apoptotic proteins different from BCL-2, reducing their priming for apoptosis.(37) This fact may lie at the basis of the reduced clinical benefit observed with venetoclax in FL patients.”
BackgroundMethodTherapeutics Targeting the Core Apoptotic Machinery
Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A. (2021) · Cancers · doi:10.3390/cancers13112618 · Cited by 26
“Cancer cells are dependent on a relatively small number of anti-apoptotic proteins for their survival, including the anti-apoptotic B-cell lymphoma family (BCL-2) proteins, inhibitors of apoptosis proteins (IAPs) and cellular Fas-associated death domain (FADD)-like IL1β (Interleukin-1β)-converting enzyme-inhibitory pr…”
BackgroundRendo, V., Lee, E. Q., Bossi, C., Khuu, N., Rudek, M. A., Pal, S., Azazmeh, N., Rashid, R., Lin, J.-R., Cusick, M., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adn6274 · Cited by 19
“To further characterize the mechanism by which continuous navtemad-lin treatment may induce cell death in glioma cells, we conducted an analysis of BH3 mimetics ( 22 ) in TP53 wild-type and mutant GBM cell lines after drug treatment (50 nM for 30 hours).”
Metadata
- Authors
- Potter, D. S., & Letai, A.
- Venue
- Cold Spring Harbor Symposia on Quantitative Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016
- Volume
- 81
- Pages
- 131-140
- ISSN
- 0091-7451 (ISSN-L)
- 1943-4456
- OpenAlex
- W2546559417
- Cited by
- 64
- References
- 15
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: To Prime, or Not to Prime: That Is the Question. https://app.cochat.ai/papers/10.1101/sqb.2016.81.030841
- The paper
- Potter, D. S., & Letai, A. (2016). To Prime, or Not to Prime: That Is the Question. Cold Spring Harbor Symposia on Quantitative Biology. https://doi.org/10.1101/sqb.2016.81.030841
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.